Download PDF
Fortschr Neurol Psychiatr 2014; 82(4): 210-219
DOI: 10.1055/s-0033-1355776
Übersicht
© Georg Thieme Verlag KG Stuttgart · New York

Immunologische Behandlungsoptionen bei schizophrenen Störungen

Immunological Treatment Options for Schizophrenia
N. Müller
1   Klinik für Psychiatrie und Psychotherapie, Klinikum der LMU München
,
D. Krause
1   Klinik für Psychiatrie und Psychotherapie, Klinikum der LMU München
,
E. Weidinger
1   Klinik für Psychiatrie und Psychotherapie, Klinikum der LMU München
,
M. Schwarz
2   Institut für Labormedizin, LMU München
› Author Affiliations
Further Information

Publication History

Publication Date:
07 April 2014 (online)

    Permissions and Reprints

Zusammenfassung

Der pathophysiologische Mechanismus, der bei Schizophrenie zur dopaminergen Dysfunktion führt, ist nach wie vor unklar. Ein entzündliches Geschehen scheint dabei eine Schlüsselrolle zu spielen. Eine Dysfunktion in der Aktivierung der Typ-1-Immunantwort ist mit verminderter Aktivität des Schlüsselenzyms im Tryptophan-Kynurenin-Metabolismus, Indolamin-2,3-Dioxygenase (IDO), assoziiert, was zu gesteigerter Produktion von Kynureninsäure – eines N-Methyl-D-Aspartat (NMDA)-Antagonisten – im ZNS und verminderter glutamatergen Neurotransmission führt. Die differenzielle Aktivierung von Mikrogliazellen und Astrozyten als funktionellen Trägern des Immunsystems im ZNS, trägt zur Typ-1-/Typ-2-Inbalance bei. Antipsychotika, die vor allem als Dopamin-D2-Rezeptor-Antagonisten wirken, haben verschiedene Nachteile. Die Immuneffekte vieler Antipsychotika rebalancieren teilweise die Dysbalance der Typ-1-/Typ-2-Immunantwort und die Überproduktion von Kynureninsäure. Das entzündliche Geschehen ist verbunden mit höherer Prostaglandin-E2(PGE-2)-Produktion und erhöhter Cyclooxygenase-2(COX-2)-Expression. Zunehmende Evidenz aus klinischen Studien mit COX-2-Inhibitoren weisen auf einen günstigen Effekt antiinflammatorischer Therapie bei Schizophrenie hin, speziell in frühen Stadien der Krankheit. Weitere Optionen von immunmodulatorischer Therapie bei Schizophrenie werden diskutiert.

Abstract

The pathophysiological mechanism leading to dopaminergic dysfunction in schizophrenia is still unclear. Inflammation seems to play a key role. A dysfunction in the activation of the type 1 immune response is associated with decreased activity of the key enzyme of the tryptophan/kynurenine metabolism, indolamine-2.3-dioxygenase (IDO), results in a higher production of kynurenine acid (KYNA) – an N-methyl-D-aspartate antagonist – in the central nervous system (CNS) and decreased glutamatergic neurotransmission. The differential activation of microglial cells and astrocytes, which serve as immune cells in the CNS, contributes to the TH1-TH2 immune imbalance. Antipsychotics, all acting as dopamine D2 receptor antagonists show several shortcomings. The immune effects of antipsychotics rebalance partly the imbalance of the type-1/type-2 immune response and the overproduction of KYNA. The inflammation is associated with higher prostaglandin E2 (PGE2) production and higher cyclo-oxygenase-2 (COX-2) expression. Increasing evidence from clinical studies with COX-2 inhibitors points to an advantageous effect of anti-inflammatory therapy in schizophrenia, especially in the early stages of the disease. Further options of immunomodulatory therapy in schizophrenia are discussed.

Schlüsselwörter

COX-2-Inhibition - Inflammation - Psychoneuro-Immunologie - Schizophrenie - Therapie

Key words

COX-2 inhibition - inflammation - psychoneuroimmunology - schizophrenia - therapy
 

  • Literatur

  • 1 Müller N, Schwarz MJ. Immune System and Schizophrenia. Curr Immunol Rev 2010; 6: 213-220
    CrossrefPubMedGoogle Scholar
  • 2 Müller N, Schwarz MJ. Immunological Treatment Options for Schizophrenia. Curr Pharm Biotechnol 2012; 13: 1606-1613
    CrossrefPubMedGoogle Scholar
  • 3 Müller N, Myint AM, Schwarz MJ. Inflammation in schizophrenia. Am J Psychiatry 2012; (in press)
    PubMedGoogle Scholar
  • 4 Purcell SM, Wray NR, Stone JL et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009; 460: 748-752
    Google Scholar
  • 5 Shi J, Levinson DF, Duan J et al. Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 2009; 460: 753-757
    Google Scholar
  • 6 Stefansson H, Ophoff RA, Steinberg S et al. Common variants conferring risk of schizophrenia. Nature 2009; 460: 744-747
    Google Scholar
  • 7 Costa E, Dong E, Grayson DR et al. Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics 2007; 2: 29-36
    CrossrefPubMedGoogle Scholar
  • 8 Kawasaki H, Iwamuro S. Potential roles of histones in host defense as antimicrobial agents. Infect Disord Drug Targets 2008; 8: 195-205
    CrossrefPubMedGoogle Scholar
  • 9 Fellerhoff B, Laumbacher B, Mueller N et al. Associations between Chlamydophila infections, schizophrenia and risk of HLA-A10. Mol Psychiatry 2007; 12: 264-272
    PubMedGoogle Scholar
  • 10 Gu S, Fellerhoff B, Müller N et al. Paradoxical downregulation of HLA-A expression by IFNgamma associated with schizophrenia and noncoding genes. Immunobiology 2013; 218: 738-744
    CrossrefPubMedGoogle Scholar
  • 11 Winter C, Djodari-Irani A, Sohr R et al. Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int J Neuropsychopharmacol 2009; 12: 513-524
    CrossrefPubMedGoogle Scholar
  • 12 Zuckerman L, Weiner I. Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring. J Psychiatr Res 2005; 39: 311-323
    CrossrefPubMedGoogle Scholar
  • 13 Brown AS. Prenatal infection as a risk factor for schizophrenia. Schizophr Bull 2006; 32: 200-202
    CrossrefPubMedGoogle Scholar
  • 14 Ellman LM, Deicken RF, Vinogradov S et al. Structural brain alterations in schizophrenia following fetal exposure to the inflammatory cytokine interleukin-8. Schizophr Res 2010; 121: 46-54
    CrossrefPubMedGoogle Scholar
  • 15 Swerdlow NR, van Bergeijk DP, Bergsma F et al. The Effects of Memantine on Prepulse Inhibition. Neuropsychopharmacology 2009; 34: 1854-1864
    CrossrefPubMedGoogle Scholar
  • 16 Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007; 12: 988-1000
    CrossrefPubMedGoogle Scholar
  • 17 Müller N, Schwarz MJ. The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neurotransmission 2007; (Suppl. 72) 269-280
    PubMedGoogle Scholar
  • 18 Spellberg B, Edwards JE Jr. Type 1/Type 2 immunity in infectious diseases. Clin Infect Dis 2001; 32: 76-102
    CrossrefPubMedGoogle Scholar
  • 19 Mills CD, Kincaid K, Alt JM et al. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164: 6166-6173
    Google Scholar
  • 20 Miller BJ, Buckley P, Seabolt W et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011; 70: 663-671
    CrossrefPubMedGoogle Scholar
  • 21 Potvin S, Stip E, Sepehry AA et al. Inflammatory Cytokine Alterations in Schizophrenia: A Systematic Quantitative Review. Biol Psychiatry 2008; 63: 801-808
    Google Scholar
  • 22 Müller N, Empl M, Riedel M et al. Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1997; 247: 308-313
    CrossrefPubMedGoogle Scholar
  • 23 Sperner-Unterweger B, Miller C, Holzner B et al. Measurement of neopterin, kynurenine and tryptophan in sera of schizophrenic patients. In: Müller N, Hrsg Psychiatry, Psychoimmunology, and viruses. Wien, New York: Springer; 1999: 115-119
    CrossrefGoogle Scholar
  • 24 Schennach H, Murr C, Gachter E et al. Factors influencing serum neopterin concentrations in a population of blood donors. Clin Chem 2002; 48: 643-645
    PubMedGoogle Scholar
  • 25 Murr C, Widner B, Wirleitner B et al. Neopterin as a marker for immune system activation. Curr Drug Metab 2002; 3: 175-187
    Google Scholar
  • 26 Chittiprol S, Venkatasubramanian G, Neelakantachar N et al. Oxidative stress and neopterin abnormalities in schizophrenia: a longitudinal study. J Psychiatr Res 2010; 44: 310-313
    CrossrefPubMedGoogle Scholar
  • 27 Duch DS, Woolf JH, Nichol CA et al. Urinary excretion of biopterin and neopterin in psychiatric disorders. Psychiatry Res 1984; 11: 83-89
    CrossrefPubMedGoogle Scholar
  • 28 Bechter K, Reiber H, Herzog S et al. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 2010; 44: 321-330
    CrossrefPubMedGoogle Scholar
  • 29 Nikkilä HV, Muller K, Ahokas A et al. Increased frequency of activated lymphocytes in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr Res 2001; 49: 99-105
    CrossrefPubMedGoogle Scholar
  • 30 Korte S, Arolt V, Peters M et al. Increased serum neopterin levels in acutely ill and recovered schizophrenic patients. Schizophr Res 1998; 32: 63-67
    CrossrefPubMedGoogle Scholar
  • 31 Müller N, Ackenheil M, Hofschuster E et al. Cellular immunity in schizophrenic patients before and during neuroleptic treatment. Psychiatry Res 1991; 37: 147-160
    CrossrefPubMedGoogle Scholar
  • 32 Schwarz MJ, Riedel M, Ackenheil M et al. Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol Psychiatry 2000; 47: 29-33
    CrossrefPubMedGoogle Scholar
  • 33 Ogawa A, Yoshizaki A, Yanaba K et al. The differential role of L-selectin and ICAM-1 in Th1-type and Th2-type contact hypersensitivity. J Invest Dermatol 2010; 130: 1558-1570
    CrossrefPubMedGoogle Scholar
  • 34 Varga G, Nippe N, Balkow S et al. LFA-1 contributes to signal I of T-cell activation and to the production of T(h)1 cytokines. J Invest Dermatol 2010; 130: 1005-1012
    CrossrefPubMedGoogle Scholar
  • 35 Haack M, Hinze-Selch D, Fenzel T et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 1999; 33: 407-418
    CrossrefPubMedGoogle Scholar
  • 36 Molholm HB. Hyposensitivity to foreign protein in schizophrenic patients. Psychiatr Quarterly 1942; 16: 565-571
    PubMedGoogle Scholar
  • 37 Riedel M, Spellmann I, Schwarz MJ et al. Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res 2007; 41: 3-7
    Google Scholar
  • 38 Bresee C, Rapaport MH. Persistently increased serum soluble interleukin-2 receptors in continuously ill patients with schizophrenia. Int J Neuropsychopharmacol 2009; 12: 861-865
    CrossrefPubMedGoogle Scholar
  • 39 Kim YK, Myint AM, Lee BH et al. Th1, Th2 and Th3 cytokine alteration in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 1129-1134
    CrossrefPubMedGoogle Scholar
  • 40 Arolt V, Rothermundt M, Wandinger KP et al. Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol Psychiatry 2000; 5: 150-158
    CrossrefPubMedGoogle Scholar
  • 41 Wilke I, Arolt V, Rothermundt M et al. Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. Eur Arch Psychiatry Clin Neurosci 1996; 246: 279-284
    CrossrefPubMedGoogle Scholar
  • 42 Avgustin B, Wraber B, Tavcar R. Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J 2005; 46: 268-274
    PubMedGoogle Scholar
  • 43 Smith RS, Maes M. The macrophage-T-lymphocyte theory of schizophrenia: additional evidence. Med Hypotheses 1995; 45: 135-141
    CrossrefPubMedGoogle Scholar
  • 44 Cazzullo CL, Scarone S, Grassi B et al. Cytokines production in chronic schizophrenia patients with or without paranoid behaviour. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 947-957
    CrossrefPubMedGoogle Scholar
  • 45 Lin A, Kenis G, Bignotti S et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 1998; 32: 9-15
    CrossrefPubMedGoogle Scholar
  • 46 Sperner-Unterweger B, Whitworth A, Kemmler G et al. T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophr Res 1999; 38: 61-70
    CrossrefPubMedGoogle Scholar
  • 47 van Kammen DP, McAllister-Sistilli CG, Kelley ME. Relationship between immune and behavioral measures in schizophrenia. In: Wieselmann G, Hrsg. Current Update in Psychoimmunology. Wien, New York: Springer; 1997: 51-55
    CrossrefGoogle Scholar
  • 48 Mittleman BB, Castellanos FX, Jacobsen LK et al. Cerebrospinal fluid cytokines in pediatric neuropsychiatric disease. J Immunol 1997; 159: 2994-2999
    PubMedGoogle Scholar
  • 49 Müller N, Riedel M, Schwarz MJ et al. Immunomodulatory effects of neuroleptics to the cytokine system and the cellular immune system in schizophrenia. In: Wieselmann G, Hrsg. Current update in psychoimmunology. Wien, New York: Springer; 1997: 57-67
    CrossrefGoogle Scholar
  • 50 Maes M, Bosmans E, Kenis G et al. In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res 1997; 26: 221-225
    CrossrefPubMedGoogle Scholar
  • 51 Ozek M, Toreci K, Akkok I et al. Influence of therapy on antibody-formation. Psychopharmacologia 1971; 21: 401-412
    CrossrefPubMedGoogle Scholar
  • 52 Müller N, Riedel M, Hadjamu M et al. Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia. Am J Psychiatry 1999; 156: 634-636
    PubMedGoogle Scholar
  • 53 Pollmächer T, Schuld A, Kraus T et al. On the clinical relevance of clozapine-triggered release of cytokines and soluble cytokine-receptors. Fortschr Neurol Psychiatr 2001; 69 (Suppl. 02) S65-S74
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Suvisaari J, Loo BM, Saarni SE et al. Inflammation in psychotic disorders: a population-based study. Psychiatry Res 2011; 189: 305-311
    CrossrefPubMedGoogle Scholar
  • 55 Pollmächer T, Haack M, Schuld A et al. Effects of antipsychotic drugs on cytokine networks. J Psychiatr Res 2000; 34: 369-382
    CrossrefPubMedGoogle Scholar
  • 56 Tanaka KF, Shintani F, Fujii Y et al. Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Res 2000; 96: 75-80
    CrossrefPubMedGoogle Scholar
  • 57 Maes M, Bosmans E, De Jongh R et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997; 9: 853-858
    CrossrefPubMedGoogle Scholar
  • 58 Müller N, Riedel M, Ackenheil M et al. Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation. World J Biol Psychiatry 2000; 1: 173-179
    CrossrefPubMedGoogle Scholar
  • 59 Brown AS, Begg MD, Gravenstein S et al. Serologic evidence of prenatal influenza in the etiology of schizophrenia. Arch Gen Psychiatry 2004; 61: 774-780
    CrossrefPubMedGoogle Scholar
  • 60 Buka SL, Goldstein JM, Seidman LJ et al. Maternal recall of pregnancy history: accuracy and bias in schizophrenia research. Schizophr Bull 2000; 26: 335-350
    CrossrefPubMedGoogle Scholar
  • 61 Meyer U, Schwarz MJ, Müller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther 2011; 132: 96-110
    CrossrefPubMedGoogle Scholar
  • 62 Gattaz WF, Abrahao AL, Foccacia R. Childhood meningitis, brain maturation and the risk of psychosis. Eur Arch Psychiatry Clin Neurosci 2004; 254: 23-26
    CrossrefPubMedGoogle Scholar
  • 63 Brown AS. The risk for schizophrenia from childhood and adult infections. Am J Psychiatry 2008; 165: 7-10
    Google Scholar
  • 64 Dalman C, Allebeck P, Gunnell D et al. Infections in the CNS during childhood and the risk of subsequent psychotic illness: a cohort study of more than one million Swedish subjects. Am J Psychiatry 2008; 165: 59-65
    CrossrefPubMedGoogle Scholar
  • 65 Koponen H, Rantakallio P, Veijola J et al. Childhood central nervous system infections and risk for schizophrenia. Eur Arch Psychiatry Clin Neurosci 2004; 254: 9-13
    CrossrefPubMedGoogle Scholar
  • 66 Körschenhausen DA, Hampel HJ, Ackenheil M et al. Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes. Schizophr Res 1996; 19: 103-109
    CrossrefPubMedGoogle Scholar
  • 67 Bechter K. Mild encephalitis underlying psychiatric disorders – A reconsideration and hypothesis exemplified on Borna disease. Neurol Psychiatry Brain Res 2001; 9: 55-70
    PubMedGoogle Scholar
  • 68 Müller N, Bechter K. The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings. Neurology, Psychiatry and Brain Research 19 2013; 87-101
    PubMedGoogle Scholar
  • 69 Lambertsen KL, Clausen BH, Babcock AA et al. Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J Neurosci 2009; 29: 1319-1330
    CrossrefPubMedGoogle Scholar
  • 70 Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007; 10: 1387-1394
    CrossrefPubMedGoogle Scholar
  • 71 Bernstein HG, Steiner J, Bogerts B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother 2009; 9: 1059-1071
    CrossrefPubMedGoogle Scholar
  • 72 Block ML, Zecca L, Hong JS. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69
    CrossrefPubMedGoogle Scholar
  • 73 Jack CS, Arbour N, Manusow J et al. TLR signaling tailors innate immune responses in human microglia and astrocytes. J Immunol 2005; 175: 4320-4330
    CrossrefPubMedGoogle Scholar
  • 74 Downes CE, Crack PJ. Neural injury following stroke: are Toll-like receptors the link between the immune system and the CNS?. Br J Pharmacol 2010; 160: 1872-1888
    CrossrefPubMedGoogle Scholar
  • 75 Bonartsev PD. An electron microscopic study of typical lymphocytes and atypical cells of peripheral blood in patients with schizophrenia. Zh Nevrol Psikhiatr Im S S Korsakova 2008; 108: 62-68
    PubMedGoogle Scholar
  • 76 Rothermundt M, Arolt V, Weitzsch C et al. Immunological dysfunction in schizophrenia: a systematic approach. Neuropsychobiology 1998; 37: 186-193
    CrossrefPubMedGoogle Scholar
  • 77 Shintani F, Kanba S, Maruo N et al. Serum interleukin-6 in schizophrenic patients. Life Sci 1991; 49: 661-664
    CrossrefPubMedGoogle Scholar
  • 78 Maes M, Meltzer HY, Bosmans E. Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine. Acta Psychiatr Scand 1994; 89: 346-351
    CrossrefPubMedGoogle Scholar
  • 79 Maes M, Bosmans E, Calabrese J et al. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 1995; 29: 141-152
    CrossrefPubMedGoogle Scholar
  • 80 Naudin J, Mege JL, Azorin JM et al. Elevated circulating levels of IL-6 in schizophrenia. Schizophr Res 1996; 20: 269-273
    CrossrefPubMedGoogle Scholar
  • 81 Wong CT, Tsoi WF, Saha N. Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophr Res 1996; 22: 165-171
    CrossrefPubMedGoogle Scholar
  • 82 Maes M, Delange J, Ranjan R et al. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res 1997; 66: 1-11
    CrossrefPubMedGoogle Scholar
  • 83 Rudduck C, Beckman L, Franzen G et al. C3 and C6 complement types in schizophrenia. Hum Hered 1985; 35: 255-258
    CrossrefPubMedGoogle Scholar
  • 84 Mayilyan KR, Arnold JN, Presanis JS et al. Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neurosci Lett 2006; 404: 336-341
    CrossrefPubMedGoogle Scholar
  • 85 Drexhage RC, Knijff EM, Padmos RC et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010; 10: 59-76
    CrossrefPubMedGoogle Scholar
  • 86 Rothermundt M, Falkai P, Ponath G et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 2004; 9: 897-899
    CrossrefPubMedGoogle Scholar
  • 87 Steiner J, Bielau H, Brisch R et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008; 42: 151-157
    Google Scholar
  • 88 Müller N, Wagner JK, Krause D et al. Impaired monocyte activation in schizophrenia. Psychiatry Res 2012; 198: 341-346
    CrossrefPubMedGoogle Scholar
  • 89 Bayer TA, Buslei R, Havas L et al. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999; 271: 126-128
    Google Scholar
  • 90 Radewicz K, Garey LJ, Gentleman SM et al. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 2000; 59: 137-150
    Google Scholar
  • 91 Wierzba-Bobrowicz T, Lewandowska E, Lechowicz W et al. Quantitative analysis of activated microglia, ramified and damage of processes in the frontal and temporal lobes of chronic schizophrenics. Folia Neuropathol 2005; 43: 81-89
    PubMedGoogle Scholar
  • 92 Na KS, Kim YK. Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology 2007; 56: 55-63
    CrossrefPubMedGoogle Scholar
  • 93 van Berckel BN, Bossong MG, Boellaard R et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008; 64: 820-822
    CrossrefPubMedGoogle Scholar
  • 94 Doorduin J, de Vries EF, Willemsen AT et al. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009; 50: 1801-1807
    CrossrefPubMedGoogle Scholar
  • 95 Takano A, Arakawa R, Ito H et al. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int J Neuropsychopharmacol 2010; 13: 943-950
    CrossrefPubMedGoogle Scholar
  • 96 Fernstrom JD. Effects on the diet on brain neurotransmitters. Metabolism 1977; 26: 207-223
    CrossrefPubMedGoogle Scholar
  • 97 Erhardt S, Schwieler L, Engberg G. Kynurenic acid and schizophrenia. Adv Exp Med Biol 2003; 527: 155-165
    PubMedGoogle Scholar
  • 98 Erhardt S, Blennow K, Nordin C et al. Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett 2001; 313: 96-98
    CrossrefPubMedGoogle Scholar
  • 99 Linderholm KR, Skogh E, Olsson SK et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull 2012; 38: 426-432
    CrossrefPubMedGoogle Scholar
  • 100 Ceresoli-Borroni G, Rassoulpour A, Wu HQ et al. Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm 2006; 113 (10) 1355-1365
    CrossrefPubMedGoogle Scholar
  • 101 Schwarcz R, Rassoulpour A, Wu HQ et al. Increased cortical kynurenate content in schizophrenia. Biol Psychiatry 2001; 50: 521-530
    CrossrefPubMedGoogle Scholar
  • 102 Miller CL, Llenos IC, Dulay JR et al. Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Res 2006; 1073-1074: 25-37
    CrossrefPubMedGoogle Scholar
  • 103 Kim YK, Myint AM, Verkerk R et al. Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology 2009; 59: 123-129
    CrossrefPubMedGoogle Scholar
  • 104 Heyes MP, Chen CY, Major EO et al. Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem J 1997; 326: 351-356
    CrossrefPubMedGoogle Scholar
  • 105 Kiss C, Ceresoli-Borroni G, Guidetti P et al. Kynurenate production by cultured human astrocytes. J Neural Transm 2003; 110: 1-14
    PubMedGoogle Scholar
  • 106 Guillemin GJ, Kerr SJ, Smythe GA et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem 2001; 78: 842-853
    CrossrefPubMedGoogle Scholar
  • 107 Chiarugi A, Carpenedo R, Moroni F. Kynurenine disposition in blood and brain of mice: effects of selective inhibitors of kynurenine hydroxylase and of kynureninase. J Neurochem 1996; 67: 692-698
    PubMedGoogle Scholar
  • 108 Wagner von Jauregg J. Fieberbehandlung bei Psychosen. Wien Med Wochenschr 1926; 76: 79-82
    PubMedGoogle Scholar
  • 109 Müller N, Schwarz MJ, Riedel M. COX-2 inhibition in schizophrenia: focus on clinical effects of celecoxib therapy and the role of TNF-alpha. In: Eaton WW, Hrsg. Medical and psychiatric comorbidity over the course of life. Washington DC: American Psychiatric Publishing; 2005: 265-276
    Google Scholar
  • 110 Ross BM, Seguin J, Sieswerda LE. Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid?. Lipids Health Dis 2007; 6: 21
    CrossrefPubMedGoogle Scholar
  • 111 Amminger GP, Schafer MR, Papageorgiou K et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010; 67: 146-154
    CrossrefPubMedGoogle Scholar
  • 112 Ehrenreich H, Hinze-Selch D, Stawicki S et al. Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry 2007; 12: 206-220
    CrossrefPubMedGoogle Scholar
  • 113 Wüstenberg T, Begemann M, Bartels C et al. Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia. Mol Psychiatry 2011; 16: 26-36
    CrossrefPubMedGoogle Scholar
  • 114 Chaves C, Marque CR, Chaudhry IB et al. Short-term improvement by minocycline added to olanzapine antipsychotic treatment in paranoid schizophrenia. Schizophr Bull 2009; 19 (Suppl. 01) 354
    PubMedGoogle Scholar
  • 115 Ahuja N, Carroll BT. Possible anti-catatonic effects of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 968-969
    CrossrefPubMedGoogle Scholar
  • 116 Mizoguchi H, Takuma K, Fukakusa A et al. Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology 2008; 196: 233-241
    CrossrefPubMedGoogle Scholar
  • 117 Levkovitz Y, Mendlovich S, Riwkes S et al. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia. J Clin Psychiatry 2010; 71: 138-149
    CrossrefPubMedGoogle Scholar
  • 118 Chaudhry IB, Hallak J, Husain N et al. Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment. J Psychopharmacol 2012; 26: 1185-1193
    CrossrefPubMedGoogle Scholar
  • 119 Dickerson FB, Boronow JJ, Stallings CR et al. Reduction of symptoms by valacyclovir in cytomegalovirus-seropositive individuals with schizophrenia. Am J Psychiatry 2003; 160: 2234-2236
    CrossrefPubMedGoogle Scholar
  • 120 Dickerson FB, Stallings CR, Boronow JJ et al. Double blind trial of adjunctive valacyclovir in individuals with schizophrenia who are seropositive for cytomegalovirus. Schizophr Res 2009; 107: 147-149
    CrossrefPubMedGoogle Scholar
  • 121 Dickerson FB, Stallings CR, Boronow JJ et al. A double-blind trial of adjunctive azithromycin in individuals with schizophrenia who are seropositive for Toxoplasma gondii. Schizophr Res 2009; 112: 198-199
    CrossrefPubMedGoogle Scholar
  • 122 Schwieler L, Erhardt S, Erhardt C et al. Prostaglandin-mediated control of rat brain kynurenic acid synthesis – opposite actions by COX-1 and COX-2 isoforms. J Neural Transm 2005; 112: 863-872
    CrossrefPubMedGoogle Scholar
  • 123 Müller N, Riedel M, Scheppach C et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002; 159: 1029-1034
    CrossrefPubMedGoogle Scholar
  • 124 Müller N, Riedel M, Dehning S et al. Is the therapeutic effect of celecoxib in schizophrenia depending from duration of disease?. Neuropsychopharmacology 2004; 29: 176
    PubMedGoogle Scholar
  • 125 Litherland SA, Xie XT, Hutson AD et al. Aberrant prostaglandin synthase 2 expression defines an antigen-presenting cell defect for insulin-dependent diabetes mellitus. J Clin Invest 1999; 104: 515-523
    CrossrefPubMedGoogle Scholar
  • 126 Müller N, Ulmschneider M, Scheppach C et al. COX-2 inhibition as a treatment approach in schizophrenia: immunological considerations and clinical effects of celecoxib add-on therapy. Eur Arch Psychiatry Clin Neurosci 2004; 254: 14-22
    CrossrefPubMedGoogle Scholar
  • 127 Casolini P, Catalani A, Zuena AR et al. Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat. J Neurosci Res 2002; 68: 337-343
    CrossrefPubMedGoogle Scholar
  • 128 Zhang Y, Chun ChenD, Long TanY et al. A double-blind, placebo-controlled trial of celecoxib addes to risperidone in first-episode and drug-naive patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006; 256 (Suppl. 02) 50
    PubMedGoogle Scholar
  • 129 Akhondzadeh S, Tabatabaee M, Amini H et al. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 2007; 90: 179-185
    CrossrefPubMedGoogle Scholar
  • 130 Rapaport MH, Delrahim KK, Bresee CJ et al. Celecoxib augmentation of continuously ill patients with schizophrenia. Biol Psychiatry 2005; 57: 1594-1596
    CrossrefPubMedGoogle Scholar
  • 131 Müller N, Krause D, Dehning S et al. Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010; 121: 119-124
    PubMedGoogle Scholar
  • 132 Müller N, Riedel M, Schwarz MJ et al. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005; 255: 149-151
    CrossrefPubMedGoogle Scholar
  • 133 Cumiskey D, Curran BP, Herron CE et al. A role for inflammatory mediators in the IL-18 mediated attenuation of LTP in the rat dentate gyrus. Neuropharmacology 2007; 52: 1616-1623
    CrossrefPubMedGoogle Scholar
  • 134 Melnikova T, Savonenko A, Wang Q et al. Cycloxygenase-2 activity promotes cognitive deficits but not increased amyloid burden in a model of Alzheimer's disease in a sex-dimorphic pattern. Neuroscience 2006; 141: 1149-1162
    CrossrefPubMedGoogle Scholar
  • 135 Sommer IE, de Witte L, Begemann M et al. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry 2012; 73: 414-419
    CrossrefPubMedGoogle Scholar
  • 136 Nitta M, Kishimoto T, Müller N et al. Adjunctive Use of Nonsteroidal Anti-inflammatory Drugs for Schizophrenia: A Meta-analytic Investigation of Randomized Controlled Trials. Schizophr Bull 2013; May 29 [Epub ahead of print]
    PubMedGoogle Scholar
  • 137 Peet M, Brind J, Ramchand CN et al. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49: 243-251
    CrossrefPubMedGoogle Scholar
  • 138 Berger GE. Ethyl-eicosapentaenoic acid (E-EPA) supplementation in early psychosis: A double-blind randomised placebo-controlled add on study in 80 drug-naive first episode psychosis patients. Int J Neuropsychopharmacol 2004; 8: S422
    PubMedGoogle Scholar
  • 139 Fenton WS, Dickerson F, Boronow J et al. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158: 2071-2074
    CrossrefPubMedGoogle Scholar
  • 140 Peet M, Horrobin DF. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36: 7-18
    CrossrefPubMedGoogle Scholar
  • 141 Emsley R, Myburgh C, Oosthuizen P et al. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychiatry 2002; 159: 1596-1598
    CrossrefPubMedGoogle Scholar
  • 142 Emsley R, Niehaus DJ, Koen L et al. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res 2006; 84: 112-120
    CrossrefPubMedGoogle Scholar
  • 143 Rappart F, Müller N. Celecoxib Add-on Therapy does not have beneficial antipsychotic Effects over Risperidone alone in Schizophrenia. Neuropsychopharmacol 2004; 29 (Suppl. 01) 222
    PubMedGoogle Scholar